Anal Carcinoma

P2, N=47, Completed, Centre Hospitalier Universitaire de Besancon | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Nov 2024 | Trial primary completion date: Sep 2024 --> Mar 2024

P3, N=308, Active, not recruiting, Incyte Corporation | Trial completion date: Oct 2024 --> Mar 2026 | Trial primary completion date: Oct 2024 --> Apr 2024

Understanding these inflammatory processes, including roles of CD8 + T cells and PD-1/PD-L1, could guide development of immunotherapies against anal cancer. This review summarizes current knowledge on inflammation's role in anal cancer pathogenesis and the interplay between HPV, HIV, and host immune factors.

P=N/A, N=167, Completed, Taproot Health | Recruiting --> Completed | N=100000 --> 167 | Trial completion date: Oct 2031 --> Oct 2024 | Trial primary completion date: Oct 2029 --> Oct 2024

P3, N=9000, Active, not recruiting, Shanghai Bovax Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting

P1, N=31, Active, not recruiting, Sumitomo Pharma America, Inc. | Trial completion date: Oct 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> Mar 2025

P=N/A, N=28, Recruiting, University of California, San Francisco | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Dec 2024 --> Dec 2025

P1, N=32, Active, not recruiting, Baylor College of Medicine | Trial primary completion date: Oct 2024 --> Oct 2025

P2, N=25, Completed, Sun Yat-sen University | Enrolling by invitation --> Completed | Trial completion date: Jun 2024 --> Nov 2024

P1, N=26, Completed, Nykode Therapeutics ASA | Active, not recruiting --> Completed | N=60 --> 26

Additionally, by coupling the molecular analysis with an interactome investigation, we hypothesized a potential functional interplay between the Ca2+ channel Transient Receptor Potential Ankyrin 1 (TRPA1) and FGFR2c, mediated by 16E5 during the establishment of the oncogenic signaling. These findings will help to elucidate the actual relevance of 16E5 in the early progression of anal lesions and contribute to determine its potential as target for future preventive approaches for HPV16-positive SCCA.

P=N/A, N=0, Withdrawn, Travera Inc | N=630 --> 0 | Not yet recruiting --> Withdrawn

P=N/A, N=500, Recruiting, Universitair Ziekenhuis Brussel

P=N/A, N=8000, Not yet recruiting, First Affiliated Hospital of Kunming Medical University; First Affiliated Hospital of Kunming Medical University

P=N/A, N=300, Not yet recruiting, Fudan University

P1, N=15, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Oct 2024 | Trial primary completion date: Jul 2025 --> Oct 2024

P=N/A, N=360, Recruiting, Cedars-Sinai Medical Center | Trial primary completion date: Jun 2025 --> Jan 2026

P2, N=77, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024

P=N/A, N=100, Not yet recruiting, University of California, San Francisco

P=N/A, N=409, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2026

Additionally, HDAC6 and DNMT3B are emerging as important therapeutic targets for cancer. This study lays the foundation for further exploration of the oncogenic mechanisms of HPV E6/E7 and may provide new directions for the treatment of HPV-related cancers.

P2, N=192, Active, not recruiting, MacroGenics | Trial primary completion date: Feb 2025 --> Jul 2024

P1, N=105, Terminated, Incyte Corporation | Trial completion date: Jun 2026 --> Aug 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Aug 2024; A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.

P=N/A, N=60, Not yet recruiting, Tata Memorial Centre

P=N/A; N=500; Not yet recruiting; Sponsor:Lisa Flowers

P=N/A, N=33, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

The addition of immunotherapy to CRT may be an effective first-line treatment option with favourable survival outcomes and acceptable toxicity for patients with ASCC. A prospective, randomized trial assessing the efficacy of CRT combined with a PD-1 inhibitor in patients with locally advanced ASCC is in progress.

Transgenic K14E6/E7 mice with established high-grade anal dysplasia were treated topically at the anus with the protease inhibitor saquinavir (SQV) in the setting of CD4+ T-cell depletion to mimic immunodeficiency...The CD4-depleted mice treated with DMBA had significantly increased tumor-free survival and overall survival as well as decreased tumor-volume growth over time when treated with SQV. These data suggest that topical SQV, in the setting of CD4 depletion and high-grade anal dysplasia, can increase tumor-free and overall survival; thus, it may represent a viable topical therapy to decrease the risk of progression of anal dysplasia to anal cancer.

P3, N=205, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

P1, N=95, Terminated, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Aug 2024 | Active, not recruiting --> Terminated; Inadequate accrual rate

P1, N=95, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Aug 2024 --> May 2024

The association between higher BMI and increased HIF-1α expression may provide insights into the interplay between metabolic health and tumor biology in ASCC. Further studies with larger cohorts are needed to validate these findings and explore targeted therapies focusing on HIF-1α modulation.

P3, N=600, Recruiting, Sahlgrenska University Hospital, Sweden | Trial primary completion date: Dec 2023 --> Oct 2024

P1, N=200, Active, not recruiting, SOTIO Biotech AG | Trial primary completion date: Aug 2024 --> Dec 2024

P2, N=192, Active, not recruiting, MacroGenics | N=382 --> 192 | Trial completion date: May 2027 --> Feb 2025 | Trial primary completion date: May 2027 --> Feb 2025

We will go into great depth regarding the diagnostic challenges in this instance and provide an outline of our approach. The immunohistochemical and prognostic importance of this case will also be covered.

The recurrence of superficial angiomyxoma is previously described, but in our case no signs of recurrence were seen in follow-up for a period of 6 months. Superficial angiomyxoma should be considered as differential diagnosis with other polypoid or nodular masses in anal canal.

With dose reduction in heterozygous patients, toxicity was within the range of patients without DPYD variants. Our clinical data suggest that dose-adapted 5‑FU-/capecitabine-chemoradiotherapy regimens can be safely considered in patients with heterozygous clinically relevant DPYD variants, but that the optimal dosage still needs to be determined to avoid both increased toxicity and undertreatment in a curative setting.

P=N/A, N=33, Not yet recruiting, Washington University School of Medicine

nHPV vaccine in adult WLHIV is immunogenic and safe.

Immunohistochemistry confirmed positivity for p63, CK5/6, and BCL2. Respect the treatment, due to the involvement of the anal sphincteric muscle, radiotherapy was chosen.

Clinical questions are arising regarding the role of immunotherapy in the adjuvant/perioperative setting, optimal timing of surgery in patients who respond to immunotherapy, and toxicities specific to patients with gastrointestinal malignancies. We outline the current landscape and future horizon of immunotherapy in gastrointestinal cancers, such as strategies to increase effectiveness of checkpoint blockade through combinations with other checkpoint inhibitors, cytotoxic chemotherapy, targeted agents, radiotherapy, CAR-T therapy, and cancer vaccines.